Fig 3. Average daily dose of guideline-recommended treatments prescribed around the time of incident heart failure in patients diagnosed from 2012–2014.

Average daily dose prescribed to patients with heart failure and reduced ejection fraction without drug-specific contraindications or intolerances, from 3 months prior up to 12 months following incident heart failure, in patients diagnosed between 2012 and 2014, smoothed with local polynomial regression. Average daily dose is expressed as a percentage of the guideline-recommended target dose. ACE-I, angiotensin-converting–enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist.